Any residual soluble

ferric iron is further sequestered through high affinity binding by innate immune proteins such as lactoferrin and transferrin [2]. For many pathogenic microbes, decreasing iron availability leads to the enhanced expression of iron acquisition mechanisms and virulence factors, which frequently play direct roles in liberating iron from host Tipifarnib cost sequestration factors [2–4]. A prevalent component of bacterial iron responses is the secretion https://www.selleckchem.com/products/PLX-4032.html of siderophores. These small molecules scavenge residual ferric iron as well as transferrin-bound iron from the extracellular milieu with extremely high affinity and are actively reimported into bacterial cells via dedicated ABC-type transport systems [5, 6]. Siderophore assembly pathways fall into two broad classes: nonribosomal peptide synthesis (NRPS)

and NRPS-independent siderophore (NIS) synthesis [7, 8]. NRPS siderophores are peptidic constructs assembled in a stepwise fashion by large, heterofunctional, multidomain proteins, independently of ribosomes. NIS siderophores are formed via condensation of alternating subunits of dicarboxylic acids with diamines, amino alcohols, and alcohols by sets of synthetase enzymes. Encoded within the genome of S. aureus are two loci directing the production of NIS-type siderophores. The sfaABCD locus encodes for proteins involved in biosynthesis and secretion of staphyloferrin A, a molecule also produced by the majority of less pathogenic coagulase-negative staphylococci Dibutyryl-cAMP supplier [9–12]. This metabolite is assembled from one unit of the nonproteinogenic amino acid D-ornithine and two units of citrate; the staphyloferrin A biosynthetic pathway was recently established in an elegant study [10]. The sbnABCDEFGHI operon encodes for biosynthesis and secretion of staphyloferrin B. This siderophore has been identified in S. aureus and a few species of coagulase-negative

staphylococci, and in the Gram-negative genera Ralstonia and Cupriavidus [13–16]. However, based on early studies by Haag et al. [16] and recent staphylococcal genome data, staphyloferrin B may also be produced by other coagulase-positive staphylococci other than S. aureus. Staphyloferrin B is comprised of one unit each of citric acid, 1,2-diaminoethane, 4-Aminobutyrate aminotransferase alpha-ketoglutaric acid, and the nonproteinogenic amino acid L-2,3-diaminopropionic acid (L-Dap) [15–17]. These precursors are condensed by NIS synthetase enzymes SbnC, SbnE, and SbnF, with modification of an intermediate metabolite by decarboxylase SbnH [17]. Inactivation of staphyloferrin B biosynthesis (via chromosomal deletion of a siderophore synthetase) was previously shown to reduce the virulence of S. aureus in a mouse infection model [14], which underscores the contribution of specialized iron uptake mechanisms to pathogenesis.

: The type III secretion effector NleE inhibits NF-kappaB activation. PLoS Pathog 6(1):e1000743. 16. Newton HJ, Pearson JS, Badea L, Kelly M, Lucas

M, Holloway G, Wagstaff KM, Dunstone MA, Sloan J, Whisstock JC, et al.: The type III effectors NleE and NleB from enteropathogenic E. coli and OspZ from Shigella block nuclear translocation of NF-kappaB p65. PLoS Pathog 6(5):e1000898. 17. Cornelis GR: The type III secretion injectisome. Nat Rev Microbiol 2006,4(11):811–825.PubMedCrossRef 18. Schraidt O, Lefebre MD, Brunner MJ, Schmied WH, Schmidt A, Radics J, Mechtler K, Galan JE, Marlovits TC: Topology and organization of the Salmonella typhimurium type III secretion needle complex components. Z IETD FMK PLoS Pathog 6(4):e1000824. 19. Kubori T, Sukhan A, Aizawa SI, Galan JE: Molecular characterization CUDC-907 supplier and assembly of the needle complex of the Salmonella typhimurium type III protein secretion system. Proc Natl Acad Sci USA 2000,97(18):10225–10230.PubMedCrossRef 20. Ogino T, Ohno R, Sekiya K, Kuwae A, Matsuzawa T, Nonaka T, Fukuda H, Imajoh-Ohmi S, Abe A: Assembly of the type III secretion apparatus of enteropathogenic Escherichia coli . J Bacteriol 2006,188(8):2801–2811.PubMedCrossRef 21. Daniell SJ, Takahashi N, Wilson R, Friedberg D, Rosenshine I, Booy FP, Shaw RK, Knutton S,

Frankel G, Aizawa S: The filamentous type III secretion translocon of enteropathogenic Escherichia coli . Cell Microbiol 2001,3(12):865–871.PubMedCrossRef 22. Creasey EA, Friedberg D, Shaw RK, Umanski T, Knutton S, Rosenshine I, Frankel G: CesAB is an enteropathogenic

Escherichia coli chaperone for the type-III translocator proteins EspA and EspB. Microbiology 2003,149(Pt 12):3639–3647.PubMedCrossRef 23. Ferris HU, Furukawa Y, Minamino T, Kroetz MB, Kihara M, Namba K, selleck screening library Macnab RM: FlhB regulates ordered export of flagellar components via autocleavage mechanism. J Biol Chem 2005,280(50):41236–41242.PubMedCrossRef 24. Riordan KE, Schneewind O: YscU cleavage and the assembly of Yersinia Pregnenolone type III secretion machine complexes. Mol Microbiol 2008,68(6):1485–1501.PubMedCrossRef 25. Minamino T, Macnab RM: Domain structure of Salmonella FlhB, a flagellar export component responsible for substrate specificity switching. J Bacteriol 2000,182(17):4906–4914.PubMedCrossRef 26. Zarivach R, Deng W, Vuckovic M, Felise HB, Nguyen HV, Miller SI, Finlay BB, Strynadka NC: Structural analysis of the essential self-cleaving type III secretion proteins EscU and SpaS. Nature 2008,453(7191):124–127.PubMedCrossRef 27. Deane JE, Graham SC, Mitchell EP, Flot D, Johnson S, Lea SM: Crystal structure of Spa40, the specificity switch for the Shigella flexneri type III secretion system. Mol Microbiol 2008,69(1):267–276.PubMedCrossRef 28. Lountos GT, Austin BP, Nallamsetty S, Waugh DS: Atomic resolution structure of the cytoplasmic domain of Yersinia pestis YscU, a regulatory switch involved in type III secretion.

1 (3.1) −2.1 (−3.2– − 0.9)* SF-36#  Selisistat supplier Physical function 80.5 (8.2) 96.6 (5.7) 16.1 (12.9–19.3)* 69.8 (22.8) 94.7 (8.1) 24.9 (19.8–30.0)*  Physical role 80.4 (32.8) 93.1 (19.2) 12.7 (1.3–24.1)* 56.6 (43.5) 93.4 (19.6) 36.8 (26.4–47.2)*  Bodily pain 71.9 (12.8) 90.3 (12.7) 18.4 (11.5–25.3)* 64.3 (19.1) 92.1 (9.9) 27.8 (23.2–32.4)*  General health 48.2 (18.3) 75.0 (13.7) 26.8 (19.2–34.4)*

52.6 (18.7) 76.7 (15.0) 24.1 (18.4–29.8)*  Social function 92.0 (11.6) 91.3 (13.2) −0.70 (−7.8–6.4) 74.5 (20.4) 90.6 (11.8) 16.1 (11.0–21.2)*  Emotional role 95.2 (17.8) 96.7 (15.3) 1.5 (−6.9–9.9) 82.0 (32.9) 91.8 (23.5) 9.8 (1.0–18.6)*  Mental health 80.6 (11.3) 72.4 (10.2) −8.2 (−13.8– − 2.6)* 73.7 (13.7) 71.0 (9.0) −2.7 (−6.3–0.9)  Vitality 66.4 (13.2) 69.1 (11.5) 2.7 (−3.6–9.0) 59.8(16.6) 66.0 (13.0) 6.2 (1.6–10.8)* Differences between early OA (CHECK) and healthy workers

* p < 0.05; selleck inhibitor Selleckchem SRT1720 # mean (SD) Health status comparison The subjects with OA reported statistically significantly lower scores than the healthy workers on the physical component of SF-36, for both sexes. On the mental component, the CHECK women also scored statistically significantly lower than the healthy subjects, with exception of the mental health scale. The scores on the mental component of SF-36 for the male healthy workers and the men with OA were similar, but on the mental health subscale, the men with OA scored significantly higher than the healthy working men. Thalidomide Because of the higher mean age and the small number of the male subjects with OA, afterwards a corrected analysis was performed, in which they were compared to an age-matched subsample of 30 healthy workers (mean age 58). This analysis generated similar results on all scales (not presented here). The healthy working men and women had very similar scores, whereas in the OA subjects, the men scored higher than the women. Functional capacity comparison The FCE test results for the male subjects are presented for

separate age categories and for the total group (Table 2). Table 2 FCE performances of male subjects with early OA (CHECK, n = 15) and male healthy workers (n = 183) FCE test Age category # (years) Early OA mean (SD) Healthy workers mean (SD) Mean difference healthy—early OA (95% CI) Lifting low (kg) 45–54 31.8 (7.4) 44.9 (12.3) 13.2 (1.0–25.4)* 55–65 34.1 (6.1) 43.0 (14.5) 9.0 (3.5–14.4)* All 33.5 (6.3) 44.3 (13.0) 10.9 (7.0–14.8)* Lifting Overhead (kg) 45–54 19.8 (2.9) 20.1 (4.8) 0.4 (−4.4–5.2) 55–65 17.3 (3.9) 18.9 (4.6) 1.6 (−1.4–4.5) All 17.9 (3.7) 19.7 (4.8) 1.8 (−0.7–4.3) Carry 2 hand (kg) 45–54 46.3 (13.4) 46.4 (11.0) 0.1 (−11.0–11.3) 55–65 35.7 (11.5) 43.1 (12.7) 7.4 (−0.9–15.7) All 38.5 (12.5) 45.4 (11.7) 7.0 (0.7–13.1)* Overhead work (s) 45–54 236 (103) 269 (127) 33 (−93–160) 55–65 207 (61) 270 (102) 63 (−0.4–127.1) All 214 (72) 270 (119) 55 (−7–117) Dynamic bend (s) 45–54 51 (7) 47 (6) −4 (–11–3) 55–65 62 (16) 66 (128) 4 (−74–82) All 60 (15) 48 (7) −12 (3–21)* Rep.

*P < 0.01 versus SCR. WT1 is involved in the regulation of cell proliferation by miR-15a/16-1 Because miR-15a/16-1 inhibit leukemic cells proliferation and suppress WT1 protein expression, we are interested in examining whether miR-15/16-1 play a role in the regulation

of cell proliferation via WT1 regulation. To examine the functional role of WT1 in leukemic cell proliferation, we used siRNA specific for WT1. WT1 mRNA and protein levels were estimated by quantitative real-time PCR and Western blotting individually. WT1 siRNA-treated K562 and learn more HL-60 cells showed a significant reduction of WT1 mRNA level after 24 and 48 h as compared to k562 and HL-60 control cells (Figure 4A). The down-regulation of WT1 in k562 and HL-60 achieved up to 64% and 68% respectively at 48 hours after siRNA transfection. Furthermore the reduction of mRNA using siRNA resulted in an obvious decrease of WT1 protein level after 48 h in K562 and HL-60

selleck screening library cell lines (Figure 4B). Finally we observed that the growth rates of k562 and HL-60 cells were significantly reduced by siRNA-WT1 compared with negative control through CCK-8 assay (Figure 4C and 4D), which resembling that of miR-15a/16-1 over-expression. Figure 4 The role of miR-15a/16-1 in the regulation of leukemic cell proliferation. (A) and (B) K562 and HL-60 cells were incubated with 1.5 ug siRNA-WT1, 1.5 ug N.C or BYL719 mw neither of the above for 24 and 48 hours, then the relative expression of WT1 and the corresponding WT1 protein level were separately measured by quantitative real-time PCR and Western blotting. (C) and (D) K562 and HL-60 cells treated with siRNA or N.C or neither of the above were measured Clomifene by CCK-8

assay at different time periods. Data are shown as mean ± SD from three independent experiments. *P < 0.05 versus negative control. The levels of miR-15a/16-1 are inversely correlated with WT1 protein expression in leukemic cells Finally we checked for the existence of a correlation between the expression levels of miR-15a or miR-16-1 by qRT-PCR and the WT1 protein levels by Western blotting in 25 AML samples and 5 normal controls. As Figure 5A indicated, whereas in two normal control cells the levels of both miRNAs were high and the WT1 protein was expressed at low levels, in six leukemic cells both miR-15a and miR-16-1 were expressed at low levels and WT1 was highly expressed. To assess the clinical relevance of these findings, we correlated WT1 protein level with miR-15a/16-1 expression in 25 AML samples and 5 normal controls. As indicated in Figure 5B and 5C, When WT1 protein levels were plotted against that of miR-15a/16-1 in each normal control and AML samples, a significant inverse correlation was found (miR-15a verse WT1 R = -0.73 P < 0.01; miR-16-1 verse WT1 R = -0.76 P < 0.01).

The substituent at N8 is in an equatorial position. The best plane of the furan ring and the C1/C2/C4/C5 plane make an angle 69.42(9)° and the dihedral angle between the planes of the furan and benzene rings is 72.50(8)°. The compound II molecule adopts a folded conformation with an angle between the furan and benzene rings of 63.29(8)° and between the best plane of the furan ring and the C1/C2/C4/C5 plane of 87.56(9)°.

This conformation is stabilized by an intramolecular N15–H15A···O25 and C26–H26C···O27 hydrogen bonds. As a result of N15–H15A···O25 interaction a six-membered ring see more is formed and make an angle 9.2(1)° with the phenyl ring. The piperidine moiety assumes a chair conformation and the substituent at N8 is in an equatorial position. Conformations TSA HDAC concentration of both methoxy groups are different. The disposition of these groups with respect to the phenyl ring can be described by the torsion angles C18–C19–O25–C26 of −107.8(2)° and C21–C20–O27–C28 of 11.1(3)°. In consequence, the methyl carbon atom C26 is found to be 1.107(4) Å out of the phenyl plane, and C28 atom is almost coplanar with this ring. The pharmacophore structure is a reflection template of the geometrical distribution of property centers localized in molecule and determines to

large extent its biological activity. It means that even subtle differences in the geometry of structurally similar molecules can significantly impact on their affinity to receptor binding Pembrolizumab clinical trial site. The comparative analysis of the studied pharmacophores was intended to find the specific properties and geometrical parameters which are crucial for the strength of binding of potential ligands to the receptors of interest. The second step of the applied procedure devoted to the selection of the potential agonists or antagonists of the studied receptors relies on docking of the reference compounds I and II to the models of the D2 receptor (Sakhteman et al., 2011). From analysis of in vitro results (Table 1) follows that the both studied compounds (I, II)

are very poorly being bounded to 5-HT1A and 5-HT2A receptors. Indeed, the model docking of compounds I and II to these receptors also showed that such binding cannot take place. The both molecules of compounds I and II were placed outside the receptor binding pockets. Thus, only docking of compounds I and II to D2 receptor is selleck compound detailed analyzed. The most discriminative parameters which distinctly classify the quality of docking are number and strength (equivalently length and geometry) of the hydrogen bonds formed between ligand and specific amino acids not only inside the receptor binding pocket but also, although to a less degree, intermolecular interactions of other types e.g., hydrophobic and edge-to-face. Table 1 5HT1A, 5HT2A, and D2 receptor affinities Ligand Receptor [K(nM)] 5HT1A 5HT2A D2 Compound I 6,100 6,000 1,000 Compound II 3,000 744.5 26.

Nat Med 2007, 13:1510–1514.Selleckchem IWR 1 PubMedCrossRef 40. Wright JS 3rd, Jin R, Novick RP: Transient interference with staphylococcal quorum sensing blocks abscess formation. Proc Natl Acad Sci USA 2005, 102:1691–1696.PubMedCrossRef 41. Traber KE, Lee E, Benson S, Corrigan R, Cantera M, Shopsin B, Novick RP: agr function in clinical staphylococcus aureus isolates. Microbiology 2008, 154:2265–2274.PubMedCrossRef 42. Park SY, Chong

YP, Park HJ, Park KH, Moon SM, Jeong JY, Kim MN, Kim SH, Lee SO, Choi SH, Woo JH, Kim YS: agr dysfunction Milciclib price and persistent methicillin-resistant staphylococcus aureus bacteremia in patients with removed eradicable foci. Infection 2013, 41:111–119.PubMedCrossRef 43. Falkow S: Bacterial entry into eukaryotic cells. Cell 1991, 65:1099–1102.PubMedCrossRef 44. Garzoni C, François P, Huyghe A, Couzinet S, Tapparel C, Charbonnier Y, Renzoni A, Lucchini S, Lew DP, Vaudaux P, Kelley WL, Schrenzel J: A global view of staphylococcus aureus whole genome expression upon internalization in human epithelial cells. BMC Genomics 2007, 8:171.PubMedCrossRef 45. Wesson CA, Liou LE, Todd KM, Bohach GA, Trumble WR, Bayles KW: Staphylococcus aureus Agr and Sar global regulators https://www.selleckchem.com/products/pifithrin-alpha.html influence internalization and induction of

apoptosis. Infect Immun 1998, 66:5238–5243.PubMed 46. Pozzi C, Waters EM, Rudkin JK, Schaeffer CR, Lohan AJ, Tong P, Loftus BJ, Pier GB, Fey PD, Massey RC, O’Gara JP: Methicillin resistance alters the biofilm phenotype and attenuates virulence

in staphylococcus aureus device-associated infections. PLoS Pathog 2012, 8:e1002626.PubMedCrossRef 47. Rudkin JK, Edwards AM, Bowden MG, Brown EL, Pozzi C, Waters EM, Chan WC, Williams P, O’Gara JP, Massey RC: Methicillin resistance reduces the virulence of Dapagliflozin healthcare-associated methicillin-resistant staphylococcus aureus by interfering with the agr quorum sensing system. J Infect Dis 2012, 205:798–806.PubMedCrossRef 48. Morfeldt E, Tegmark K, Arvidson S: Transcriptional control of the agr -dependent virulence gene regulator, RNAIII, in staphylococcus aureus . Mol Microbiol 1996, 21:1227–1237.PubMedCrossRef 49. Beenken KE, Mrak LN, Griffin LM, Zielinska AK, Shaw LN, Rice KC, Horswill AR, Bayles KW, Smeltzer MS: Epistatic relationships between sarA and agr in staphylococcus aureus biofilm formation. PLoS One 2010, 5:e10790.PubMedCrossRef 50. CLSI: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 9th edition. Wayne, PA: CLSI document M07-A9. Clinical and Laboratory Standards Institute; 2012. 51. De Jonge BLM, De Lencastre H, Tomasz A: Supression of autolysis and cell wall turnover in heterogeneous Tn 551 mutants of a methicillin-resistant staphylococcus aureus strain. J Bacteriology 1991, 173:1105–1110. 52.

PubMedCrossRef 9. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, et al.: COT

drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010,468(7326):968–972.PubMedCrossRef 10. Di-Poi N, Tan NS, Michalik L, Wahli W, Desvergne B: Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell 2002,10(4):721–733.PubMedCrossRef 11. Ballard DW, Dixon EP, Peffer NJ, Bogerd H, Doerre S, Stein B, Greene WC: The 65-kDa subunit of human NF-kappa B functions as a potent transcriptional activator and a target for v-Rel-mediated repression. selleck inhibitor Proc Natl Acad Sci U S A 1992,89(5):1875–1879.PubMedCrossRef 12. JSH-23 datasheet Yamasaki D, Kawabe N, Nakamura H, Tachibana K, Ishimoto K, Tanaka T, Aburatani H, Sakai J, Hamakubo T, Kodama T, et al.: Fenofibrate suppresses growth of the human hepatocellular carcinoma cell via PPARalpha-independent mechanisms. Eur J Cell Biol 2011,90(8):657–664.PubMedCrossRef 13. Hsin IL, Sheu GT, Chen HH, Chiu LY, Wang HD, Chan HW, Hsu CP, Ko JL: N-acetyl cysteine mitigates curcumin-mediated

telomerase inhibition through rescuing of Sp1 reduction in A549 cells. Mut Res 2010,688(1–2):72–77. 14. Srivastava RK, Rahman Q, Kashyap MP, Lohani M, Pant AB: Ameliorative effects of dimetylthiourea and N-acetylcysteine on nanoparticles induced ARS-1620 mw cyto-genotoxicity in human lung cancer cells-A549. PLoS One 2011,6(9):e25767.PubMedCrossRef 15. Peifer C, Alessi DR: Small-molecule inhibitors of PDK1. ChemMedChem 2008,3(12):1810–1838.PubMedCrossRef 16.

Pozzi A, Ibanez MR, Gatica AE, Yang S, Wei S, Mei S, Falck JR, Capdevila JH: Peroxisomal proliferator-activated Etofibrate receptor-alpha-dependent inhibition of endothelial cell proliferation and tumorigenesis. J Biol Chem 2007,282(24):17685–17695.PubMedCrossRef 17. Yokoyama Y, Xin B, Shigeto T, Umemoto M, Kasai-Sakamoto A, Futagami M, Tsuchida S, Al-Mulla F, Mizunuma H: Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer. Mol Cancer Ther 2007,6(4):1379–1386.PubMedCrossRef 18. Drukala J, Urbanska K, Wilk A, Grabacka M, Wybieralska E, Del Valle L, Madeja Z, Reiss K: ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARalpha -mediated inhibition of glioma cell motility in vitro . Mol Cancer 2010, 9:159.PubMedCrossRef 19. Yu S, Levi L, Siegel R, Noy N: Retinoic acid induces neurogenesis by activating both retinoic acid receptors (RARs) and peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta). J Biol Chem 2012,287(50):42195–42205.PubMedCrossRef 20. Pedchenko TV, Gonzalez AL, Wang D, DuBois RN, Massion PP: Peroxisome proliferator-activated receptor beta/delta expression and activation in lung cancer. Am J Respir Cell Mol Biol 2008,39(6):689–696.PubMedCrossRef 21. Chung J, Irwin MS: Targeting the p53-family in cancer and chemosensitivity: triple threat.

In undisturbed and unstimulated groundwater systems the primary STAT inhibitor carbon sources available may include humic acids and complex mixtures of carbohydrates that derive from the breakdown of vegetation inputs and cell wall constituents, as well as volatile fatty acids derived from the microbial breakdown of such inputs [24, 25]. Microbial activity in these systems is thought to be primarily driven by fermenters of complex carbohydrates, with subsequent utilization of fermentation products such as acetate, ethanol and other volatile fatty acids by sulfate reducing bacteria (SRB) and ferric

iron reducing bacteria (FRB) that oxidize these products Selleckchem SB203580 [26–30]. As a first step towards developing a model anaerobic and syntrophic community, we sought to use 3 to 4 model organisms to serve as archetypes for the various functional redox groups. All candidate microorganisms have sequenced genomes http://​genome.​jgi-psf.​org/​cloce/​cloce.​info.​html[31, www.selleckchem.com/products/sn-38.html 32], tractable genetic systems [33–36], and have been previously studied individually or in co-culture in continuous flow systems [37–42].

Clostridium cellulolyticum was chosen as the basal organism due the diverse ability of this organism for the fermentation of complex carbohydrate polymers. As it ferments cellobiose, for example, acetate, lactate, ethanol and hydrogen are produced that can potentially be used by other organisms including SRB and FRB. The secondary stage in the chain of nutrient and electron flow was represented by both Desulfovibrio vulgaris and by Geobacter sulfurreducens, each of which can utilize the metabolites of C. cellulolyticum. In this system, D. vulgaris and G. sulfurreducens were provided with sulfate and fumarate, respectively, as electron-acceptors in

order to avoid electron-acceptor competition as well as the precipitates from using ferric iron as an electron-acceptor for Geobacter. Both Desulfovibrio-like and Geobacter-like organisms also represent organisms commonly responsible for the reduction of Uranium, Chromium and click here other heavy metals as found in contaminated sites [27–30, 43, 44]. By constructing this consortia from the a priori criteria described above, we were also able to quickly refine minimal medium and cultivation conditions. This strategy also enables the future development and application of analytical methods that take full advantage of genome enabled tools to characterize and track consortia dynamics at the molecular level. The goals of this study were to; 1) develop a stable microbial consortia in continuous flow systems that could be used for physiological and functional genomic studies in tractable and manipulable experiments, 2) to develop and apply analytical methods for quantifying the community members and monitoring individual as well as community metabolism, and 3) to build a simple metabolic model of the community. Here we present analysis of a stable consortium comprised of C. cellulolyticum, D. vulgaris, and G.